Usnic acid based thiazole-hydrazones as multi-targeting inhibitors of a wide spectrum of SARS-CoV-2 viruses
Although the Covid-19 pandemic is officially over and the spread of coronavirus infection is no longer considered an international emergency, the virus continues to persist in the population, supporting the process of mutagenesis, which may lead to the emergence of more dangerous variants that can c...
Saved in:
Published in | New journal of chemistry Vol. 47; no. 43; pp. 19865 - 19879 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
CAMBRIDGE
Royal Soc Chemistry
06.11.2023
Royal Society of Chemistry |
Subjects | |
Online Access | Get full text |
ISSN | 1144-0546 1369-9261 |
DOI | 10.1039/d3nj03598k |
Cover
Loading…
Abstract | Although the Covid-19 pandemic is officially over and the spread of coronavirus infection is no longer considered an international emergency, the virus continues to persist in the population, supporting the process of mutagenesis, which may lead to the emergence of more dangerous variants that can cause new outbreaks in the future. Therefore, the search for new effective drugs against the SARS-CoV-2 virus and other coronaviruses with a wide spectrum of activity remains an urgent task of medicinal chemistry. We synthesized a set of thiazolo-hydrazones based on (+)- and (−)-usnic acid and studied their ability to inhibit the main viral protease of the SARS-CoV-2 virus. It was shown that 9 out of 36 agents exhibit antiprotease activity in the range from 13 to 27 μM. The kinetic parameters of the four most active compounds were studied and molecular modeling of the possible interaction of these compounds with the active site of the main protease was carried out. Using six different strains (Wuhan, Delta, and four Omicron lines) of the SARS-CoV-2 virus, the antiviral activity of selected leader compounds was studied and it was shown that agent
(+)-7a
with a furan fragment has a pronounced antiviral activity against all strains. Additionally, the ability of the leading compounds to influence the stage of virus entry was studied, for which the activity of the compounds against the pseudoviral system with S glycoprotein on its surface was studied, as well as the ability to inhibit the interaction of recombinant ACE2 receptors with the RBD domain of the S protein by ELISA testing. It was found that the leading compounds are able to effectively inhibit pseudoviral particles without affecting the interaction of ACE2 and RBD. In order to search for a possible binding site for the leading compounds on the surface of the S-protein, molecular modeling was carried out. The N-terminal domain of the S protein was considered as a potential biological target, and it was found that the agents probably bind to the biliverdin site of the surface glycoprotein. Thus, we have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects.
We have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects. |
---|---|
AbstractList | Although the Covid-19 pandemic is officially over and the spread of coronavirus infection is no longer considered an international emergency, the virus continues to persist in the population, supporting the process of mutagenesis, which may lead to the emergence of more dangerous variants that can cause new outbreaks in the future. Therefore, the search for new effective drugs against the SARS-CoV-2 virus and other coronaviruses with a wide spectrum of activity remains an urgent task of medicinal chemistry. We synthesized a set of thiazolo-hydrazones based on (+)- and (−)-usnic acid and studied their ability to inhibit the main viral protease of the SARS-CoV-2 virus. It was shown that 9 out of 36 agents exhibit antiprotease activity in the range from 13 to 27 μM. The kinetic parameters of the four most active compounds were studied and molecular modeling of the possible interaction of these compounds with the active site of the main protease was carried out. Using six different strains (Wuhan, Delta, and four Omicron lines) of the SARS-CoV-2 virus, the antiviral activity of selected leader compounds was studied and it was shown that agent
(+)-7a
with a furan fragment has a pronounced antiviral activity against all strains. Additionally, the ability of the leading compounds to influence the stage of virus entry was studied, for which the activity of the compounds against the pseudoviral system with S glycoprotein on its surface was studied, as well as the ability to inhibit the interaction of recombinant ACE2 receptors with the RBD domain of the S protein by ELISA testing. It was found that the leading compounds are able to effectively inhibit pseudoviral particles without affecting the interaction of ACE2 and RBD. In order to search for a possible binding site for the leading compounds on the surface of the S-protein, molecular modeling was carried out. The N-terminal domain of the S protein was considered as a potential biological target, and it was found that the agents probably bind to the biliverdin site of the surface glycoprotein. Thus, we have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects.
We have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects. Although the Covid-19 pandemic is officially over and the spread of coronavirus infection is no longer considered an international emergency, the virus continues to persist in the population, supporting the process of mutagenesis, which may lead to the emergence of more dangerous variants that can cause new outbreaks in the future. Therefore, the search for new effective drugs against the SARS-CoV-2 virus and other coronaviruses with a wide spectrum of activity remains an urgent task of medicinal chemistry. We synthesized a set of thiazolo-hydrazones based on (+)- and (−)-usnic acid and studied their ability to inhibit the main viral protease of the SARS-CoV-2 virus. It was shown that 9 out of 36 agents exhibit antiprotease activity in the range from 13 to 27 μM. The kinetic parameters of the four most active compounds were studied and molecular modeling of the possible interaction of these compounds with the active site of the main protease was carried out. Using six different strains (Wuhan, Delta, and four Omicron lines) of the SARS-CoV-2 virus, the antiviral activity of selected leader compounds was studied and it was shown that agent (+)-7a with a furan fragment has a pronounced antiviral activity against all strains. Additionally, the ability of the leading compounds to influence the stage of virus entry was studied, for which the activity of the compounds against the pseudoviral system with S glycoprotein on its surface was studied, as well as the ability to inhibit the interaction of recombinant ACE2 receptors with the RBD domain of the S protein by ELISA testing. It was found that the leading compounds are able to effectively inhibit pseudoviral particles without affecting the interaction of ACE2 and RBD. In order to search for a possible binding site for the leading compounds on the surface of the S-protein, molecular modeling was carried out. The N-terminal domain of the S protein was considered as a potential biological target, and it was found that the agents probably bind to the biliverdin site of the surface glycoprotein. Thus, we have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects. Although the Covid-19 pandemic is officially over and the spread of coronavirus infection is no longer considered an international emergency, the virus continues to persist in the population, supporting the process of mutagenesis, which may lead to the emergence of more dangerous variants that can cause new outbreaks in the future. Therefore, the search for new effective drugs against the SARS-CoV-2 virus and other coronaviruses with a wide spectrum of activity remains an urgent task of medicinal chemistry. We synthesized a set of thiazolo-hydrazones based on (+)- and (-)-usnic acid and studied their ability to inhibit the main viral protease of the SARS-CoV-2 virus. It was shown that 9 out of 36 agents exhibit antiprotease activity in the range from 13 to 27 mu M. The kinetic parameters of the four most active compounds were studied and molecular modeling of the possible interaction of these compounds with the active site of the main protease was carried out. Using six different strains (Wuhan, Delta, and four Omicron lines) of the SARS-CoV-2 virus, the antiviral activity of selected leader compounds was studied and it was shown that agent (+)-7a with a furan fragment has a pronounced antiviral activity against all strains. Additionally, the ability of the leading compounds to influence the stage of virus entry was studied, for which the activity of the compounds against the pseudoviral system with S glycoprotein on its surface was studied, as well as the ability to inhibit the interaction of recombinant ACE2 receptors with the RBD domain of the S protein by ELISA testing. It was found that the leading compounds are able to effectively inhibit pseudoviral particles without affecting the interaction of ACE2 and RBD. In order to search for a possible binding site for the leading compounds on the surface of the S-protein, molecular modeling was carried out. The N-terminal domain of the S protein was considered as a potential biological target, and it was found that the agents probably bind to the biliverdin site of the surface glycoprotein. Thus, we have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects. We have identified new usnic acid derivatives that are active against a wide range of strains of the SARS-CoV-2 virus and have multi-targeting effects. |
Author | Mordvinova, Ekaterina D Pyankov, Oleg V Filimonov, Aleksandr S Chirkova, Varvara Yu Borisevich, Sophia S Zaykovskaya, Anna V Belenkaya, Svetlana V Yarovaya, Olga I Baev, Dmitriy S Shcherbakov, Dmitriy N Luzina, Olga A Salakhutdinov, Nariman F |
AuthorAffiliation | Leninski pr., 61 State Research Center of Virology and Biotechnology VECTOR Rospotrebnadzor Department of Medicinal Chemistry Altay State University N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS Lavrentyev av Laboratory of Chemical Physics Ufa Institute of Chemistry Ufa Federal Research Center 71 Pr. Oktyabrya |
AuthorAffiliation_xml | – sequence: 0 name: State Research Center of Virology and Biotechnology VECTOR – sequence: 0 name: Laboratory of Chemical Physics – sequence: 0 name: Ufa Institute of Chemistry Ufa Federal Research Center – sequence: 0 name: Rospotrebnadzor – sequence: 0 name: Leninski pr., 61 – sequence: 0 name: Department of Medicinal Chemistry – sequence: 0 name: Lavrentyev av – sequence: 0 name: N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS – sequence: 0 name: 71 Pr. Oktyabrya – sequence: 0 name: Altay State University |
Author_xml | – sequence: 1 givenname: Olga I surname: Yarovaya fullname: Yarovaya, Olga I – sequence: 2 givenname: Aleksandr S surname: Filimonov fullname: Filimonov, Aleksandr S – sequence: 3 givenname: Dmitriy S surname: Baev fullname: Baev, Dmitriy S – sequence: 4 givenname: Sophia S surname: Borisevich fullname: Borisevich, Sophia S – sequence: 5 givenname: Varvara Yu surname: Chirkova fullname: Chirkova, Varvara Yu – sequence: 6 givenname: Anna V surname: Zaykovskaya fullname: Zaykovskaya, Anna V – sequence: 7 givenname: Ekaterina D surname: Mordvinova fullname: Mordvinova, Ekaterina D – sequence: 8 givenname: Svetlana V surname: Belenkaya fullname: Belenkaya, Svetlana V – sequence: 9 givenname: Dmitriy N surname: Shcherbakov fullname: Shcherbakov, Dmitriy N – sequence: 10 givenname: Olga A surname: Luzina fullname: Luzina, Olga A – sequence: 11 givenname: Oleg V surname: Pyankov fullname: Pyankov, Oleg V – sequence: 12 givenname: Nariman F surname: Salakhutdinov fullname: Salakhutdinov, Nariman F |
BookMark | eNqNks9LHDEUx4NY8Ed78V4I9GaJTSaTbOYoY_3RSgvd2uuQTV7crLvJmmQU_euddWUL4sFc3iN8Pt8HedlD2yEGQOiA0SNGefPN8jCjXDTqZgvtMi4b0lSSbQ89q2tCRS130F7OM0oZG0m2i26ucvAGa-MtnugMFpep149xDmT6YNPQBchYZ7zo58WTotM1FB-usQ9TP_Elpoyjwxrfews4L8GU1C9WV-PjP2PSxn-kwnc-9RnyR_TB6XmGTy91H12dfv_bnpPL32cX7fElMZVihQjZUG25s-C4EbUbVc5KJQSMhGONc1S6Rk2MGoqQlDOrqaXOKlfpkZAAfB99WecuU7ztIZduFvsUhpFdpZSsasEFG6iva-oeJtFl4yEY6JbJL3R66IYHoorXXNLVWdHq_XTriy4-hjb2oQzq4Vo1KeacwG00RrvV1roT_uvH89Z-DjB9BZuXsJK0n7-tfF4rKZtN9P-PwJ8AchWkPg |
CitedBy_id | crossref_primary_10_3390_M1894 crossref_primary_10_1093_bib_bbae513 crossref_primary_10_1134_S1070363224010080 crossref_primary_10_3390_v16020215 |
Cites_doi | 10.1016/j.ejmech.2018.10.055 10.1007/s12033-023-00667-5 10.1016/j.bmc.2014.10.033 10.1056/NEJMoa2118542 10.1093/nar/28.1.235 10.1007/s11101-020-09717-1 10.1016/j.molstruc.2021.130506 10.1097/JS9.0000000000000276 10.1002/jmv.28326 10.3390/v14102154 10.1177/2040206616636992 10.1039/C2MD20242E 10.1128/spectrum.00563-22 10.1126/sciadv.abg7607 10.1016/j.biopha.2021.111430 10.3390/molecules24203711 10.3390/v13020174 10.1038/s41586-022-05514-2 10.1021/acscentsci.3c00538 10.3390/biom11060787 10.1038/d41586-021-03614-z 10.1007/s12010-022-04103-3 10.1038/s41467-019-13993-7 10.1002/ptr.7151 10.1002/cmdc.202000924 10.1080/14786419.2023.2235715 10.3390/chemosensors11020135 10.1080/13543776.2018.1472239 10.1007/s11356-022-19770-2 10.1016/j.bmcl.2012.09.084 10.1126/science.abb4489 10.1126/science.abb3405 10.3390/molecules27051743 10.1038/s41598-022-16964-z 10.1021/acs.jmedchem.2c01005 10.3390/v14010119 10.3390/v14061295 10.1002/mco2.239 10.1016/j.ebiom.2021.103703 10.1016/j.molstruc.2021.130665 10.1021/acs.jnatprod.2c00015 10.1039/D1SM01181B 10.2307/1221768 10.1038/s41598-022-17506-3 10.1007/s10600-012-0258-5 10.1056/NEJMoa2001017 10.1021/acsptsci.0c00130 10.1007/s13659-021-00317-w 10.1002/jmv.27541 10.1021/acs.jctc.1c00302 10.1371/journal.pone.0042846 10.1021/acs.analchem.0c02449 10.1016/S0300-9084(02)01386-X 10.1007/s41061-022-00399-1 10.1002/mco2.151 10.1038/s41467-020-16080-4 10.1039/c2md20242e 10.1039/d1sm01181b 10.1038/s41467-022-30086-0 10.1038/s41586-020-2223-y |
ContentType | Journal Article |
Copyright | Copyright Royal Society of Chemistry 2023 |
Copyright_xml | – notice: Copyright Royal Society of Chemistry 2023 |
DBID | AAYXX CITATION 17B 1KM BLEPL BNZSX DTL EGQ 7SR 8BQ 8FD H9R JG9 KA0 |
DOI | 10.1039/d3nj03598k |
DatabaseName | CrossRef Web of Knowledge Index Chemicus Web of Science Core Collection Web of Science - Science Citation Index Expanded - 2023 Science Citation Index Expanded Web of Science Primary (SCIE, SSCI & AHCI) Engineered Materials Abstracts METADEX Technology Research Database Illustrata: Natural Sciences Materials Research Database ProQuest Illustrata: Technology Collection |
DatabaseTitle | CrossRef Web of Science Materials Research Database ProQuest Illustrata: Natural Sciences Engineered Materials Abstracts ProQuest Illustrata: Technology Collection Technology Research Database METADEX |
DatabaseTitleList | CrossRef Materials Research Database Web of Science |
Database_xml | – sequence: 1 dbid: 1KM name: Index Chemicus url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC sourceTypes: Enrichment Source Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry |
EISSN | 1369-9261 |
EndPage | 19879 |
ExternalDocumentID | 001083436000001 10_1039_D3NJ03598K d3nj03598k |
GrantInformation_xml | – fundername: Synthesis of compounds, testing against a main viral protease and as inhibitors of virus entry, performing molecular modeling was supported by the Russian Science Foundation grant No 22-23-00618. Section of the study "Biological testing for an infectious v |
GroupedDBID | --- -DZ -JG -~X 0-7 0R~ 123 29N 4.4 705 70~ 7~J AAEMU AAIWI AAJAE AAMEH AANOJ AAWGC AAXHV AAXPP ABASK ABCQX ABDVN ABEMK ABJNI ABPDG ABRYZ ABXOH ACGFS ACIWK ACLDK ACNCT ADMRA ADSRN AEFDR AENEX AENGV AESAV AETIL AFLYV AFOGI AFRDS AFVBQ AGEGJ AGKEF AGRSR AGSTE AHGCF ALMA_UNASSIGNED_HOLDINGS ANUXI APEMP ASKNT AUDPV AZFZN BLAPV BSQNT C6K CS3 D0L DU5 EBS ECGLT EE0 EF- F5P GGIMP GNO H13 HZ~ H~N IDZ J3I L7B M4U N9A O9- OK1 P2P R7B R7C R7D RAOCF RCNCU RNS RPMJG RRA RRC RSCEA SKA SKF SKH SLH TN5 TWZ VH6 YNT YQT AAYXX AFRZK AKMSF ALUYA CITATION R56 17B 1KM BLEPL DTL GROUPED_WOS_SCIENCE_CITATION_INDEX_EXPANDED GROUPED_WOS_WEB_OF_SCIENCE 7SR 8BQ 8FD H9R JG9 KA0 |
ID | FETCH-LOGICAL-c281t-5690ad3fdef3c54f72fd6855e75f19ff06f98bc86f956031da0d0fd8f2a756ee3 |
ISICitedReferencesCount | 5 |
ISICitedReferencesURI | https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=001083436000001 |
ISSN | 1144-0546 |
IngestDate | Mon Jun 30 08:27:28 EDT 2025 Fri May 30 07:49:16 EDT 2025 Fri Aug 29 15:50:35 EDT 2025 Tue Jul 01 02:51:41 EDT 2025 Thu Apr 24 22:57:07 EDT 2025 Tue Dec 17 20:58:29 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 43 |
Keywords | DRUG DERIVATIVES |
Language | English |
LinkModel | OpenURL |
LogoURL | https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg |
MergedId | FETCHMERGED-LOGICAL-c281t-5690ad3fdef3c54f72fd6855e75f19ff06f98bc86f956031da0d0fd8f2a756ee3 |
Notes | https://doi.org/10.1039/d3nj03598k Electronic supplementary information (ESI) available. See DOI ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
ORCID | 0000-0002-0492-154X 0000-0002-2333-4893 0000-0003-2798-2844 0000-0001-8481-0470 |
PQID | 2886245351 |
PQPubID | 2048886 |
PageCount | 15 |
ParticipantIDs | webofscience_primary_001083436000001CitationCount rsc_primary_d3nj03598k webofscience_primary_001083436000001 crossref_primary_10_1039_D3NJ03598K crossref_citationtrail_10_1039_D3NJ03598K proquest_journals_2886245351 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023-11-06 |
PublicationDateYYYYMMDD | 2023-11-06 |
PublicationDate_xml | – month: 11 year: 2023 text: 2023-11-06 day: 06 |
PublicationDecade | 2020 |
PublicationPlace | CAMBRIDGE |
PublicationPlace_xml | – name: CAMBRIDGE – name: Cambridge |
PublicationTitle | New journal of chemistry |
PublicationTitleAbbrev | NEW J CHEM |
PublicationYear | 2023 |
Publisher | Royal Soc Chemistry Royal Society of Chemistry |
Publisher_xml | – name: Royal Soc Chemistry – name: Royal Society of Chemistry |
References | 7 Yang (D3NJ03598K/cit53/1) 2020; 92 Cowan (D3NJ03598K/cit1/1) 1983; 32 Lee (D3NJ03598K/cit33/1) 2022; 13 Hu (D3NJ03598K/cit36/1) 2022 Berman (D3NJ03598K/cit57/1) 2000; 28 Chernyshov (D3NJ03598K/cit28/1) 2022; 380 Iketani (D3NJ03598K/cit10/1) 2023; 613 La Monica (D3NJ03598K/cit34/1) 2022; 65 Rosa (D3NJ03598K/cit47/1) 2023 Sokolov (D3NJ03598K/cit4/1) 2012; 22 Mordvinova (D3NJ03598K/cit50/1) 2023; 11 Zhu (D3NJ03598K/cit8/1) 2020; 382 Filimonov (D3NJ03598K/cit24/1) 2022; 14 Jin (D3NJ03598K/cit32/1) 2020 Domingo (D3NJ03598K/cit38/1) 2021; 74 Yang (D3NJ03598K/cit35/1) 2021; 16 Lee (D3NJ03598K/cit37/1) 2020; 11 Thakur (D3NJ03598K/cit42/1) 2022; 94 Ong (D3NJ03598K/cit43/1) 2023; 95 Luzina (D3NJ03598K/cit55/1) 2012; 48 Channabasappa (D3NJ03598K/cit45/1) 2023; 109 Lockbaum (D3NJ03598K/cit56/1) 2021; 13 Merarchi (D3NJ03598K/cit13/1) 2021; 35 Ma (D3NJ03598K/cit29/1) 2020; 3 Bowers (D3NJ03598K/cit59/1) 2006 Ebob (D3NJ03598K/cit15/1) 2021; 11 Zakharenko (D3NJ03598K/cit25/1) 2019; 161 (D3NJ03598K/cit54/1) 2006 Callaway (D3NJ03598K/cit41/1) 2021; 600 Hammond (D3NJ03598K/cit9/1) 2022; 386 Campanella (D3NJ03598K/cit3/1) 2002; 84 Obakachi (D3NJ03598K/cit27/1) 2021; 1241 Dai (D3NJ03598K/cit31/1) 2020; 368 Hu (D3NJ03598K/cit40/1) 2022; 18 Shtro (D3NJ03598K/cit6/1) 2014; 22 Ao (D3NJ03598K/cit46/1) 2023; 4 Liskova (D3NJ03598K/cit16/1) 2021; 138 Prateeksha (D3NJ03598K/cit21/1) 2021; 1240 Macedo (D3NJ03598K/cit2/1) 2021; 20 Gupta (D3NJ03598K/cit20/1) 2022; 194 Filimonov (D3NJ03598K/cit26/1) 2019; 24 Yarovaya (D3NJ03598K/cit48/1) 2022; 14 Luzina (D3NJ03598K/cit7/1) 2018; 28 Caserta (D3NJ03598K/cit39/1) 2022; 10 Oh (D3NJ03598K/cit19/1) 2022; 12 Zhang (D3NJ03598K/cit30/1) 2020; 368 Shtro (D3NJ03598K/cit5/1) 2015; 24 Jalencas (D3NJ03598K/cit12/1) 2013; 4 Chhetri (D3NJ03598K/cit18/1) 2022; 85 Coban (D3NJ03598K/cit22/1) 2021; 11 Roney (D3NJ03598K/cit23/1) Suenaga (D3NJ03598K/cit60/1) 2012; 7 Rosa (D3NJ03598K/cit51/1) 2021; 7 Touret (D3NJ03598K/cit52/1) 2022; 12 González-Maldonado (D3NJ03598K/cit17/1) 2022; 27 Borisevich (D3NJ03598K/cit49/1) 2022; 14 Parums (D3NJ03598K/cit44/1) 2023; 29 Al-Harrasi (D3NJ03598K/cit14/1) 2022; 29 Hu (D3NJ03598K/cit11/1) 2023; 9 Lu (D3NJ03598K/cit58/1) 2021; 17 Macedo, DCS (WOS:000568262400001) 2021; 20 Cowan, R. S. (001083436000001.1) 1983; 32 Zakharenko, AL (WOS:000451498200040) 2019; 161 Merarchi, M (WOS:000661861200001) 2021; 35 Filimonov, AS (WOS:000496249500080) 2019; 24 Liskova, A (WOS:000641386500004) 2021; 138 Yang, Y (WOS:000563047900010) 2020; 92 Luzina, OA (WOS:000306833200009) 2012; 48 Jin, ZM (WOS:000537932300001) 2020; 582 Rosa, L (WOS:001028774700001) 2024; 38 Zhang, LL (WOS:000528513300041) 2020; 368 Thakur, V (WOS:000736131800001) 2022; 94 (001083436000001.54) 2006 Hu, YM (WOS:001035682300001) 2023 Obakachi, VA (WOS:000670212600006) 2021; 1241 Yarovaya, OI (WOS:000816661400001) 2022; 14 Mordvinova, ED (WOS:000938929200001) 2023; 11 Sokolov, DN (WOS:000310583100013) 2012; 22 Lee, JB (WOS:000790385800009) 2022; 13 Jalencas, X (WOS:000312547200011) 2013; 4 Shtro, A. A. (BCI:BCI201600792100) 2015; 24 Borisevich, SS (WOS:000749830700001) 2022; 14 Ao, DY (WOS:000949578700001) 2023; 4 Channabasappa, NK (WOS:000999427500050) 2023; 109 Lee, JY (WOS:000537248100001) 2020; 11 Domingo, P (WOS:000744272700007) 2021; 74 Callaway, E (WOS:000727856300008) 2021; 600 Gupta, A (WOS:000835626900002) 2022; 194 Ma, CL (WOS:000599606200018) 2020; 3 Chhetri, BK (WOS:000778916900022) 2022; 85 Al-Harrasi, A (WOS:000777207600005) 2022; 29 Lockbaum, GJ (WOS:000623306100001) 2021; 13 Filimonov, AS (WOS:000873640300001) 2022; 14 Hu, YW (WOS:000831276100001) 2022; 18 Luzina, OA (WOS:000433950900006) 2018; 28 Hammond, J (WOS:000755954300001) 2022; 386 Campanella, L (WOS:000177111800009) 2002; 84 Ebob, OT (WOS:000695375300001) 2021; 11 Zhu, N (WOS:000517119800008) 2020; 382 Roney, M (WOS:000929264800001) 2024; 66 Touret, F (WOS:000830058200001) 2022; 12 Oh, E (WOS:000834790800022) 2022; 12 Suenaga, A (WOS:000307733800031) 2012; 7 Rosa, A (WOS:000655906900036) 2021; 7 Chernyshov, VV (WOS:000839670500003) 2022; 380 La Monica, G (WOS:000863534600001) 2022; 65 Berman, HM (WOS:000084896300069) 2000; 28 Parums, D. V. (001083436000001.44) 2023; 29 Iketani, S (WOS:000901944300001) 2023; 613 Caserta, L. C. (001083436000001.39) 2022; 10 Hu, Q (WOS:000825282200001) 2022; 3 Dai, WH (WOS:000544017600040) 2020; 368 Yang, KS (WOS:000596948600001) 2021; 16 Lu, C (WOS:000674289800037) 2021; 17 Ong, CP (WOS:000891847500001) 2023; 95 Coban, MA (WOS:000665434600001) 2021; 11 González-Maldonado, P (WOS:000768165400001) 2022; 27 Prateeksha, G (WOS:000664244700007) 2021; 1240 Shtro, AA (WOS:000345650800011) 2014; 22 Bowers, K. J. (001083436000001.59) 2006 |
References_xml | – issn: 2006 year: 7 end-page: 1 – issn: 2006 end-page: 43 publication-title: IEEE doi: Bowers Chow Xu Dror Eastwood Gregersen Klepeis Kolossvary Moraes Sacerdoti Salmon Shan Shaw – volume: 161 start-page: 581 year: 2019 ident: D3NJ03598K/cit25/1 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2018.10.055 – ident: D3NJ03598K/cit23/1 publication-title: Mol. Biotechnol. doi: 10.1007/s12033-023-00667-5 – volume: 22 start-page: 6826 year: 2014 ident: D3NJ03598K/cit6/1 publication-title: Bioorg. Med. Chem. doi: 10.1016/j.bmc.2014.10.033 – volume: 386 start-page: 1397 year: 2022 ident: D3NJ03598K/cit9/1 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2118542 – volume: 28 start-page: 235 year: 2000 ident: D3NJ03598K/cit57/1 publication-title: Nucleic Acids Res. doi: 10.1093/nar/28.1.235 – volume: 20 start-page: 609 year: 2021 ident: D3NJ03598K/cit2/1 publication-title: Phytochem. Rev. doi: 10.1007/s11101-020-09717-1 – volume: 1240 start-page: 130506 year: 2021 ident: D3NJ03598K/cit21/1 publication-title: J. Mol. Struct. doi: 10.1016/j.molstruc.2021.130506 – volume: 109 start-page: 1054 year: 2023 ident: D3NJ03598K/cit45/1 publication-title: Int. J. Surg. doi: 10.1097/JS9.0000000000000276 – start-page: 43 volume-title: IEEE year: 2006 ident: D3NJ03598K/cit59/1 – volume: 95 start-page: e28326 year: 2023 ident: D3NJ03598K/cit43/1 publication-title: J. Med. Virol. doi: 10.1002/jmv.28326 – volume: 14 start-page: 2154 year: 2022 ident: D3NJ03598K/cit24/1 publication-title: Viruses doi: 10.3390/v14102154 – volume: 24 start-page: 92 year: 2015 ident: D3NJ03598K/cit5/1 publication-title: Antiviral Chem. Chemother. doi: 10.1177/2040206616636992 – volume: 4 start-page: 80 year: 2013 ident: D3NJ03598K/cit12/1 publication-title: MedChemComm doi: 10.1039/C2MD20242E – volume: 10 start-page: 1 year: 2022 ident: D3NJ03598K/cit39/1 publication-title: Microbiol. Spectr. doi: 10.1128/spectrum.00563-22 – volume: 7 start-page: eabg7607 year: 2021 ident: D3NJ03598K/cit51/1 publication-title: Sci. Adv. doi: 10.1126/sciadv.abg7607 – volume: 138 start-page: 111430 year: 2021 ident: D3NJ03598K/cit16/1 publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2021.111430 – volume: 24 start-page: 3711 year: 2019 ident: D3NJ03598K/cit26/1 publication-title: Molecules doi: 10.3390/molecules24203711 – volume: 13 start-page: 174 year: 2021 ident: D3NJ03598K/cit56/1 publication-title: Viruses doi: 10.3390/v13020174 – volume: 613 start-page: 558 year: 2023 ident: D3NJ03598K/cit10/1 publication-title: Nature doi: 10.1038/s41586-022-05514-2 – volume: 9 start-page: 1658 year: 2023 ident: D3NJ03598K/cit11/1 publication-title: ACS Cent. Sci. doi: 10.1021/acscentsci.3c00538 – volume: 11 start-page: 787 year: 2021 ident: D3NJ03598K/cit22/1 publication-title: Biomolecules doi: 10.3390/biom11060787 – volume: 600 start-page: 197 year: 2021 ident: D3NJ03598K/cit41/1 publication-title: Nature doi: 10.1038/d41586-021-03614-z – volume: 194 start-page: 6386 year: 2022 ident: D3NJ03598K/cit20/1 publication-title: Appl. Biochem. Biotechnol. doi: 10.1007/s12010-022-04103-3 – volume: 11 start-page: 1 year: 2020 ident: D3NJ03598K/cit37/1 publication-title: Nat. Commun. doi: 10.1038/s41467-019-13993-7 – volume: 35 start-page: 5384 year: 2021 ident: D3NJ03598K/cit13/1 publication-title: Phyther. Res. doi: 10.1002/ptr.7151 – volume: 16 start-page: 942 year: 2021 ident: D3NJ03598K/cit35/1 publication-title: ChemMedChem doi: 10.1002/cmdc.202000924 – start-page: 1 year: 2023 ident: D3NJ03598K/cit47/1 publication-title: Nat. Prod. Res. doi: 10.1080/14786419.2023.2235715 – volume: 11 start-page: 135 year: 2023 ident: D3NJ03598K/cit50/1 publication-title: Chemosensors doi: 10.3390/chemosensors11020135 – volume: 28 start-page: 477 year: 2018 ident: D3NJ03598K/cit7/1 publication-title: Expert Opin. Ther. Pat. doi: 10.1080/13543776.2018.1472239 – volume: 13 start-page: 1 year: 2022 ident: D3NJ03598K/cit33/1 publication-title: Nat. Commun. – volume: 29 start-page: 42404 year: 2022 ident: D3NJ03598K/cit14/1 publication-title: Environ. Sci. Pollut. Res. doi: 10.1007/s11356-022-19770-2 – volume: 22 start-page: 7060 year: 2012 ident: D3NJ03598K/cit4/1 publication-title: Bioorg. Med. Chem. Lett. doi: 10.1016/j.bmcl.2012.09.084 – volume: 368 start-page: 1331 year: 2020 ident: D3NJ03598K/cit31/1 publication-title: Science doi: 10.1126/science.abb4489 – volume: 368 start-page: 409 year: 2020 ident: D3NJ03598K/cit30/1 publication-title: Science doi: 10.1126/science.abb3405 – volume: 27 start-page: 1743 year: 2022 ident: D3NJ03598K/cit17/1 publication-title: Molecules doi: 10.3390/molecules27051743 – volume: 12 start-page: 12609 year: 2022 ident: D3NJ03598K/cit52/1 publication-title: Sci. Rep. doi: 10.1038/s41598-022-16964-z – volume: 65 start-page: 12500 year: 2022 ident: D3NJ03598K/cit34/1 publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.2c01005 – volume: 14 start-page: 119 year: 2022 ident: D3NJ03598K/cit49/1 publication-title: Viruses doi: 10.3390/v14010119 – volume: 14 start-page: 1295 year: 2022 ident: D3NJ03598K/cit48/1 publication-title: Viruses doi: 10.3390/v14061295 – volume: 4 start-page: e239 year: 2023 ident: D3NJ03598K/cit46/1 publication-title: MedComm doi: 10.1002/mco2.239 – volume: 74 start-page: 103703 year: 2021 ident: D3NJ03598K/cit38/1 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2021.103703 – volume: 1241 start-page: 130665 year: 2021 ident: D3NJ03598K/cit27/1 publication-title: J. Mol. Struct. doi: 10.1016/j.molstruc.2021.130665 – volume: 85 start-page: 657 year: 2022 ident: D3NJ03598K/cit18/1 publication-title: J. Nat. Prod. doi: 10.1021/acs.jnatprod.2c00015 – volume: 18 start-page: 5833 year: 2022 ident: D3NJ03598K/cit40/1 publication-title: Soft Matter doi: 10.1039/D1SM01181B – volume: 32 start-page: 698 year: 1983 ident: D3NJ03598K/cit1/1 publication-title: Taxon doi: 10.2307/1221768 – volume: 12 start-page: 13118 year: 2022 ident: D3NJ03598K/cit19/1 publication-title: Sci. Rep. doi: 10.1038/s41598-022-17506-3 – start-page: 1 year: 2020 ident: D3NJ03598K/cit32/1 publication-title: Nature – volume: 48 start-page: 385 year: 2012 ident: D3NJ03598K/cit55/1 publication-title: Chem. Nat. Compd. doi: 10.1007/s10600-012-0258-5 – volume: 382 start-page: 727 year: 2020 ident: D3NJ03598K/cit8/1 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2001017 – volume: 29 start-page: 10 year: 2023 ident: D3NJ03598K/cit44/1 publication-title: Med. Sci. Monit. – volume: 3 start-page: 1265 year: 2020 ident: D3NJ03598K/cit29/1 publication-title: ACS Pharmacol. Transl. Sci. doi: 10.1021/acsptsci.0c00130 – volume: 11 start-page: 611 year: 2021 ident: D3NJ03598K/cit15/1 publication-title: Nat. Prod. Bioprospect. doi: 10.1007/s13659-021-00317-w – volume: 94 start-page: 1821 year: 2022 ident: D3NJ03598K/cit42/1 publication-title: J. Med. Virol. doi: 10.1002/jmv.27541 – volume: 17 start-page: 4291 year: 2021 ident: D3NJ03598K/cit58/1 publication-title: J. Chem. Theory Comput. doi: 10.1021/acs.jctc.1c00302 – start-page: 3 year: 2022 ident: D3NJ03598K/cit36/1 publication-title: MedComm – volume: 7 start-page: e42846 year: 2012 ident: D3NJ03598K/cit60/1 publication-title: PLoS One doi: 10.1371/journal.pone.0042846 – volume: 92 start-page: 10930 year: 2020 ident: D3NJ03598K/cit53/1 publication-title: Anal. Chem. doi: 10.1021/acs.analchem.0c02449 – start-page: 1 year: 2006 ident: D3NJ03598K/cit54/1 – volume: 84 start-page: 329 year: 2002 ident: D3NJ03598K/cit3/1 publication-title: Biochimie doi: 10.1016/S0300-9084(02)01386-X – volume: 380 start-page: 42 year: 2022 ident: D3NJ03598K/cit28/1 publication-title: Top. Curr. Chem. doi: 10.1007/s41061-022-00399-1 – volume: 600 start-page: 197 year: 2021 ident: WOS:000727856300008 article-title: HOW BAD IS OMICRON? WHAT SCIENTISTS KNOW SO FAR publication-title: NATURE doi: 10.1038/d41586-021-03614-z – volume: 27 start-page: ARTN 1743 year: 2022 ident: WOS:000768165400001 article-title: Screening of Natural Products Inhibitors of SARS-CoV-2 Entry publication-title: MOLECULES doi: 10.3390/molecules27051743 – volume: 94 start-page: 1821 year: 2022 ident: WOS:000736131800001 article-title: OMICRON (B.1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear publication-title: JOURNAL OF MEDICAL VIROLOGY doi: 10.1002/jmv.27541 – volume: 3 start-page: ARTN e151 year: 2022 ident: WOS:000825282200001 article-title: The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19 publication-title: MEDCOMM doi: 10.1002/mco2.151 – volume: 1241 start-page: ARTN 130665 year: 2021 ident: WOS:000670212600006 article-title: Design and synthesis of pyrazolone-based compounds as potent blockers of SARS-CoV-2 viral entry into the host cells publication-title: JOURNAL OF MOLECULAR STRUCTURE doi: 10.1016/j.molstruc.2021.130665 – volume: 17 start-page: 4291 year: 2021 ident: WOS:000674289800037 article-title: OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space publication-title: JOURNAL OF CHEMICAL THEORY AND COMPUTATION doi: 10.1021/acs.jctc.1c00302 – volume: 35 start-page: 5384 year: 2021 ident: WOS:000661861200001 article-title: Natural products and phytochemicals as potential anti-SARS-CoV-2 drugs publication-title: PHYTOTHERAPY RESEARCH doi: 10.1002/ptr.7151 – volume: 29 start-page: 10 year: 2023 ident: 001083436000001.44 publication-title: Med. Sci. Monit – volume: 3 start-page: 1265 year: 2020 ident: WOS:000599606200018 article-title: Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors publication-title: ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE doi: 10.1021/acsptsci.0c00130 – volume: 194 start-page: 6386 year: 2022 ident: WOS:000835626900002 article-title: Exploration of Novel Lichen Compounds as Inhibitors of SARS-CoV-2 Mpro: Ligand-Based Design, Molecular Dynamics, and ADMET Analyses publication-title: APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY doi: 10.1007/s12010-022-04103-3 – volume: 161 start-page: 581 year: 2019 ident: WOS:000451498200040 article-title: Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topotecan on in vivo tumor models publication-title: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1016/j.ejmech.2018.10.055 – volume: 386 start-page: 1397 year: 2022 ident: WOS:000755954300001 article-title: Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 publication-title: NEW ENGLAND JOURNAL OF MEDICINE doi: 10.1056/NEJMoa2118542 – volume: 24 start-page: 92 year: 2015 ident: BCI:BCI201600792100 article-title: Derivatives of usnic acid inhibit broad range of influenza viruses and protect mice from lethal influenza infection publication-title: Antiviral Chemistry & Chemotherapy doi: 10.1177/2040206616636992 – volume: 11 start-page: ARTN 2358 year: 2020 ident: WOS:000537248100001 article-title: N-AS-triggered SPMs are direct regulators of microglia in a model of Alzheimer's disease publication-title: NATURE COMMUNICATIONS doi: 10.1038/s41467-020-16080-4 – volume: 12 start-page: ARTN 12609 year: 2022 ident: WOS:000830058200001 article-title: In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5 publication-title: SCIENTIFIC REPORTS doi: 10.1038/s41598-022-16964-z – volume: 48 start-page: 385 year: 2012 ident: WOS:000306833200009 article-title: Synthesis of aurones based on usninic acid publication-title: CHEMISTRY OF NATURAL COMPOUNDS doi: 10.1007/s10600-012-0258-5 – volume: 28 start-page: 477 year: 2018 ident: WOS:000433950900006 article-title: Usnic acid and its derivatives for pharmaceutical use: a patent review (2000-2017) publication-title: EXPERT OPINION ON THERAPEUTIC PATENTS doi: 10.1080/13543776.2018.1472239 – volume: 32 year: 1983 ident: 001083436000001.1 publication-title: Taxon – volume: 22 start-page: 6826 year: 2014 ident: WOS:000345650800011 article-title: Novel derivatives of usnic acid effectively inhibiting reproduction of influenza A virus publication-title: BIOORGANIC & MEDICINAL CHEMISTRY doi: 10.1016/j.bmc.2014.10.033 – volume: 14 start-page: ARTN 1295 year: 2022 ident: WOS:000816661400001 article-title: Borneol Ester Derivatives as Entry Inhibitors of a Wide Spectrum of SARS-CoV-2 Viruses publication-title: VIRUSES-BASEL doi: 10.3390/v14061295 – year: 2006 ident: 001083436000001.54 publication-title: RU – volume: 368 start-page: 409 year: 2020 ident: WOS:000528513300041 article-title: Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors publication-title: SCIENCE doi: 10.1126/science.abb3405 – volume: 66 start-page: 696 year: 2024 ident: WOS:000929264800001 article-title: Identification of Pyrazole Derivatives of Usnic Acid as Novel Inhibitor of SARS-CoV-2 Main Protease Through Virtual Screening Approaches publication-title: MOLECULAR BIOTECHNOLOGY doi: 10.1007/s12033-023-00667-5 – volume: 11 start-page: ARTN 787 year: 2021 ident: WOS:000665434600001 article-title: Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement publication-title: BIOMOLECULES doi: 10.3390/biom11060787 – volume: 28 start-page: 235 year: 2000 ident: WOS:000084896300069 article-title: The Protein Data Bank publication-title: NUCLEIC ACIDS RESEARCH – volume: 10 start-page: 1 year: 2022 ident: 001083436000001.39 publication-title: Microbiol. Spectr – volume: 7 start-page: ARTN eabg7607 year: 2021 ident: WOS:000655906900036 article-title: SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity publication-title: SCIENCE ADVANCES doi: 10.1126/sciadv.abg7607 – volume: 382 start-page: 727 year: 2020 ident: WOS:000517119800008 article-title: A Novel Coronavirus from Patients with Pneumonia in China, 2019 publication-title: NEW ENGLAND JOURNAL OF MEDICINE doi: 10.1056/NEJMoa2001017 – volume: 74 start-page: ARTN 103703 year: 2021 ident: WOS:000744272700007 article-title: Alpha variant SARS-CoV-2 infection: How it all starts publication-title: EBIOMEDICINE doi: 10.1016/j.ebiom.2021.103703 – volume: 24 start-page: ARTN 3711 year: 2019 ident: WOS:000496249500080 article-title: New Hydrazinothiazole Derivatives of Usnic Acid as Potent Tdp1 Inhibitors publication-title: MOLECULES doi: 10.3390/molecules24203711 – volume: 368 start-page: 1331 year: 2020 ident: WOS:000544017600040 article-title: Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease publication-title: SCIENCE doi: 10.1126/science.abb4489 – volume: 12 start-page: ARTN 13118 year: 2022 ident: WOS:000834790800022 article-title: (+)-Usnic acid and its salts, inhibitors of SARS-CoV-2, identified by using in silico methods and in vitro assay publication-title: SCIENTIFIC REPORTS doi: 10.1038/s41598-022-17506-3 – volume: 4 start-page: ARTN e239 year: 2023 ident: WOS:000949578700001 article-title: The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants publication-title: MEDCOMM doi: 10.1002/mco2.239 – volume: 4 start-page: 80 year: 2013 ident: WOS:000312547200011 article-title: On the origins of drug polypharmacology publication-title: MEDCHEMCOMM doi: 10.1039/c2md20242e – volume: 18 start-page: 5833 year: 2022 ident: WOS:000831276100001 article-title: Nanomechanical analysis of SARS-CoV-2 variants and predictions of infectiousness and lethality publication-title: SOFT MATTER doi: 10.1039/d1sm01181b – volume: 65 start-page: 12500 year: 2022 ident: WOS:000863534600001 article-title: Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/acs.jmedchem.2c01005 – year: 2006 ident: 001083436000001.59 publication-title: IEEE – volume: 13 start-page: ARTN 174 year: 2021 ident: WOS:000623306100001 article-title: Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188 publication-title: VIRUSES-BASEL doi: 10.3390/v13020174 – volume: 380 start-page: ARTN 42 year: 2022 ident: WOS:000839670500003 article-title: Nitrogen-Containing Heterocyclic Compounds Obtained from Monoterpenes or Their Derivatives: Synthesis and Properties publication-title: TOPICS IN CURRENT CHEMISTRY doi: 10.1007/s41061-022-00399-1 – volume: 85 start-page: 657 year: 2022 ident: WOS:000778916900022 article-title: Marine Natural Products as Leads against SARS-CoV-2 Infection publication-title: JOURNAL OF NATURAL PRODUCTS doi: 10.1021/acs.jnatprod.2c00015 – volume: 11 start-page: 611 year: 2021 ident: WOS:000695375300001 article-title: Natural Products as Potential Lead Compounds for Drug Discovery Against SARS-CoV-2 publication-title: NATURAL PRODUCTS AND BIOPROSPECTING doi: 10.1007/s13659-021-00317-w – volume: 109 start-page: 1054 year: 2023 ident: WOS:000999427500050 article-title: SARS-CoV-2 variant omicron XBB.1.5: challenges and prospects publication-title: INTERNATIONAL JOURNAL OF SURGERY doi: 10.1097/JS9.0000000000000276 – volume: 14 start-page: ARTN 119 year: 2022 ident: WOS:000749830700001 article-title: Simulation of Molecular Dynamics of SARS-CoV-2 S-Protein in the Presence of Multiple Arbidol Molecules: Interactions and Binding Mode Insights publication-title: VIRUSES-BASEL doi: 10.3390/v14010119 – volume: 29 start-page: 42404 year: 2022 ident: WOS:000777207600005 article-title: Targeting natural products against SARS-CoV-2 publication-title: ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH doi: 10.1007/s11356-022-19770-2 – volume: 11 start-page: ARTN 135 year: 2023 ident: WOS:000938929200001 article-title: Inhibitors of the RBD-ACE-2 Found among a Wide Range of Dyes by the Immunoassay Method publication-title: CHEMOSENSORS doi: 10.3390/chemosensors11020135 – volume: 13 start-page: ARTN 2421 year: 2022 ident: WOS:000790385800009 article-title: Rapid access to polycyclic N-heteroarenes from unactivated, simple azines via a base-promoted Minisci-type annulation publication-title: NATURE COMMUNICATIONS doi: 10.1038/s41467-022-30086-0 – volume: 92 start-page: 10930 year: 2020 ident: WOS:000563047900010 article-title: The Utility of Native MS for Understanding the Mechanism of Action of Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the SARS-CoV-2 Interaction with Its Host Cell Receptor publication-title: ANALYTICAL CHEMISTRY doi: 10.1021/acs.analchem.0c02449 – volume: 95 year: 2023 ident: WOS:000891847500001 article-title: Comparative analysis of SARS-CoV-2 Omicron BA.2.12.1 and BA.5.2 variants publication-title: JOURNAL OF MEDICAL VIROLOGY doi: 10.1002/jmv.28326 – volume: 22 start-page: 7060 year: 2012 ident: WOS:000310583100013 article-title: Anti-viral activity of (-)- and (+)-usnic acids and their derivatives against influenza virus A(H1N1)2009 publication-title: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS doi: 10.1016/j.bmcl.2012.09.084 – volume: 613 start-page: 558 year: 2023 ident: WOS:000901944300001 article-title: Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir publication-title: NATURE doi: 10.1038/s41586-022-05514-2 – volume: 20 start-page: 609 year: 2021 ident: WOS:000568262400001 article-title: Usnic acid: from an ancient lichen derivative to promising biological and nanotechnology applications publication-title: PHYTOCHEMISTRY REVIEWS doi: 10.1007/s11101-020-09717-1 – volume: 1240 start-page: ARTN 130506 year: 2021 ident: WOS:000664244700007 article-title: Screening of cryptogamic secondary metabolites as putative inhibitors of SARS-CoV-2 main protease and ribosomal binding domain of spike glycoprotein by molecular docking and molecular dynamics approaches publication-title: JOURNAL OF MOLECULAR STRUCTURE doi: 10.1016/j.molstruc.2021.130506 – volume: 14 start-page: ARTN 2154 year: 2022 ident: WOS:000873640300001 article-title: (+)-Usnic Acid and Its Derivatives as Inhibitors of a Wide Spectrum of SARS-CoV-2 Viruses publication-title: VIRUSES-BASEL doi: 10.3390/v14102154 – volume: 16 start-page: 942 year: 2021 ident: WOS:000596948600001 article-title: A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors** publication-title: CHEMMEDCHEM doi: 10.1002/cmdc.202000924 – volume: 582 start-page: 289 year: 2020 ident: WOS:000537932300001 article-title: Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors publication-title: NATURE doi: 10.1038/s41586-020-2223-y – volume: 84 start-page: 329 year: 2002 ident: WOS:000177111800009 article-title: Molecular characterization and action of usnic acid: a drug that inhibits proliferation of mouse polyomavirus in vitro and whose main target is RNA transcription publication-title: BIOCHIMIE – volume: 138 start-page: ARTN 111430 year: 2021 ident: WOS:000641386500004 article-title: Flavonoids against the SARS-CoV-2 induced inflammatory storm publication-title: BIOMEDICINE & PHARMACOTHERAPY doi: 10.1016/j.biopha.2021.111430 – volume: 38 start-page: 2129 year: 2024 ident: WOS:001028774700001 article-title: Neutralizing activity of Usnic acid and α-cyclodextrins complex against SARS-CoV-2 spike pseudovirus publication-title: NATURAL PRODUCT RESEARCH doi: 10.1080/14786419.2023.2235715 – year: 2023 ident: WOS:001035682300001 article-title: Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir publication-title: ACS CENTRAL SCIENCE doi: 10.1021/acscentsci.3c00538 – volume: 7 start-page: ARTN e42846 year: 2012 ident: WOS:000307733800031 article-title: An Efficient Computational Method for Calculating Ligand Binding Affinities publication-title: PLOS ONE doi: 10.1371/journal.pone.0042846 |
SSID | ssj0011761 |
Score | 2.4296606 |
Snippet | Although the Covid-19 pandemic is officially over and the spread of coronavirus infection is no longer considered an international emergency, the virus... |
Source | Web of Science |
SourceID | proquest webofscience crossref rsc |
SourceType | Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 19865 |
SubjectTerms | Binding sites Chemical synthesis Chemistry Chemistry, Multidisciplinary Glycoproteins Hydrazones Modelling Physical Sciences Protease Proteins Science & Technology Severe acute respiratory syndrome coronavirus 2 Viral diseases Viruses |
Title | Usnic acid based thiazole-hydrazones as multi-targeting inhibitors of a wide spectrum of SARS-CoV-2 viruses |
URI | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=001083436000001 https://www.proquest.com/docview/2886245351 |
Volume | 47 |
WOS | 001083436000001 |
WOSCitedRecordID | wos001083436000001 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa67gFeELeJwkCW2AuqMhI718fSDW0DhkQ7tLfK9YVl7ZopaYu6n8Sv5NhxkjL6UHhJI1-iuOeLz7F9zncQOiAkiZLY444fUKWPGbmTEAl3KojAwoiFNDwFX87Dkwv_7DK4bLV-rXktLebjQ363Ma7kf6QKZSBXHSX7D5KtHwoFcA_yhStIGK5byfii0OlrGE_BigRtpF0hU3aXTaVztRI53ME8phPJGK9Bp3T6LmNYrtJxavLsmPDIn6mQXRNzmS9uTBhL79vA6WffHdJdpvmisI6G1w3V0xrjBK9yxtUzCMuzJVsZs_Tr9Afrnh7WMEmnAI5ZtrTBNZOCzUTeHdQNPjBp6o5u0nmertZrMpiPQI2XuasG2S2Mtaq22xaEmvi9cG2mhZWcA_ai5cEuy2iYAFRKdvZqei4JOS0Mfbo22XpJXOaZsJpb758kG9WCSzWr6hE9PzOMhZ8a5Vcd-N_TibWnojmjp8mo6buDdgksSUgb7faOh6ef6zMrLyrZeauBVWS4NHnf9P7T_GnWNDt5wTfaPsbOGT5Gj-wCBfdKtD1BLTl7ih70Kxk_QxODOqxRhw3q8AbUYVbge6jDDepwpjDDGnW4Qp0ualCHLeqeo4uPx8P-iWNTdjicxN7cCcLEZYIqIRXlga8iokQYB4GMAuUlSrmhSuIxj-En0PnNBXOFq0SsCIuCUEq6h9ozeM0XCPthyKUnmR-Oud6EiH3hSV-5ksKzZUI66F31T4645bPXaVWmo79l1kFv67a3JYvLxlb7lUBG9isqRiTWIVQBDbwO2gMh1f0FnV2bfpMOOliXW91C77fE1KehWYlDf2-bZn07Fs1JMX-51Yu_Qg-bT2wftUFs8jXYyvPxGwvS37y6vbw |
linkProvider | Royal Society of Chemistry |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Usnic+acid+based+thiazole-hydrazones+as+multi-targeting+inhibitors+of+a+wide+spectrum+of+SARS-CoV-2+viruses&rft.jtitle=New+journal+of+chemistry&rft.au=Yarovaya%2C+Olga+I.&rft.au=Filimonov%2C+Aleksandr+S.&rft.au=Baev%2C+Dmitriy+S.&rft.au=Borisevich%2C+Sophia+S.&rft.date=2023-11-06&rft.issn=1144-0546&rft.eissn=1369-9261&rft.volume=47&rft.issue=43&rft.spage=19865&rft.epage=19879&rft_id=info:doi/10.1039%2FD3NJ03598K&rft.externalDBID=n%2Fa&rft.externalDocID=10_1039_D3NJ03598K |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1144-0546&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1144-0546&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1144-0546&client=summon |